Files and links (1)
Published, Version of Record (VoR)CC BY V4.0, Open
Journal article
COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside
NPJ Parkinson's Disease, v 6(1), pp 18-18
20 Aug 2020
PMID: 32885037
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
This Viewpoint discusses insights from basic science and clinical perspectives on coronavirus disease 2019 (COVID-19)/severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection in the brain, with a particular focus on Parkinson’s disease. Major points include that neuropathology studies have not answered the central issue of whether the virus enters central nervous system neurons, astrocytes or microglia, and the brain vascular cell types that express virus have not yet been identified. Currently, there is no clear evidence for human neuronal or astrocyte expression of angiotensin-converting enzyme 2 (ACE2), the major receptor for viral entry, but ACE2 expression may be activated by inflammation, and a comparison of healthy and infected brains is important. In contrast to the 1918 influenza pandemic and avian flu, reports of encephalopathy in COVID-19 have been slow to emerge, and there are so far no documented reports of parkinsonism apart from a single case report. We recommend consensus guidelines for the clinical treatment of Parkinson’s patients with COVID-19. While a role for the virus in causing or exacerbating Parkinson’s disease appears unlikely at this time, aggravation of specific motor and non-motor symptoms has been reported, and it will be important to monitor subjects after recovery, particularly for those with persisting hyposmia.
Metrics
Details
- Title
- COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside
- Creators
- David Sulzer - Columbia University Medical CenterAngelo Antonini - University of PaduaValentina Leta - King's College LondonAnna Nordvig - NewYork–Presbyterian HospitalRichard J. Smeyne - Thomas Jefferson UniversityJames E. Goldman - NewYork–Presbyterian HospitalOsama Al-Dalahmah - NewYork–Presbyterian HospitalLuigi Zecca - Institute of Biomedical TechnologiesAlessandro Sette - University of California, San DiegoLuigi Bubacco - University of PaduaOlimpia Meucci - Drexel UniversityElena Moro - Grenoble Alpes UniversityAshley S. Harms - University of Alabama at BirminghamYaqian Xu - Columbia University Medical CenterStanley Fahn - NewYork–Presbyterian HospitalK. Ray Chaudhuri - De Crespigny Park, London, SE5 8AF UK Denmark Hill, London, SE5 9RS UK
- Publication Details
- NPJ Parkinson's Disease, v 6(1), pp 18-18
- Publisher
- Nature Publishing Group UK
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Pharmacology and Physiology
- Web of Science ID
- WOS:000562894900001
- Scopus ID
- 2-s2.0-85089654607
- Other Identifier
- 991019167924904721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Neurosciences